COMMUNIQUÉS West-GlobeNewswire

FibroBiologics Announces Filing of Patent Application for Generation of Functional Hematopoietic Organoids using Fibroblast Cell-Based Technology
12/09/2024
HOUSTON, Sept. 12, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of [...]
Kriya Highlights Positive Preclinical Data for KRIYA-586, a Gene Therapy Product Candidate for Thyroid Eye Disease (TED), at ESOPRS Annual Meeting
12/09/2024
– Preclinical data demonstrate pharmacodynamic activity of KRIYA-586, an investigational gene therapy which encodes for an anti- IGF1R antibody – – Kriya anticipates advancing KRIYA-586 into the clinic in 2025 to [...]
University of California Transforms Life Science Research Procurement with Labviva
12/09/2024
University of California selects AI purchasing platform to accelerate scientific and research procurement for 10 campuses OAKLAND, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- The University of California (UC) has [...]
Streamline Health® Reports Fiscal Second Quarter 2024 Financial Results
11/09/2024
Net loss of ($2.8 million) during the second quarter of fiscal 2024 compared to a net loss of ($2.5 million) during the second quarter of fiscal 2023 Adjusted EBITDA improved to a loss of ($0.3 million) for the second [...]
Teva to Present at the Bank of America 2024 Global Healthcare Conference
11/09/2024
TEL AVIV, Israel, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the Bank of America 2024 [...]
iSpecimen Announces 1-for-20 Reverse Stock Split
11/09/2024
WOBURN, Mass., Sept. 11, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a [...]
Umoja Biopharma to Present at the 9th Annual CAR-TCR Summit
11/09/2024
SEATTLE, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), a transformative immunotherapy company creating off-the-shelf treatments that aim to extend the reach and effectiveness of CAR-T cell therapies [...]
Annual Report 2023/24 - Strengthened commercial focus after challenging year
11/09/2024
ANNOUNCEMENT NO. 273 11 September 2024 Annual Report 2023/24 (1 July 2023 - 30 June 2024) Strengthened commercial focus after challenging year ChemoMetec’s revenue fell by 8% in 2023/24 to DKK 407.4 million, and [...]
Guidance for the 2024/25 financial year
11/09/2024
ANNOUNCEMENT NO. 272 11 September 2024 Guidance for the 2024/25 financial year ChemoMetec has today approved the annual report for 2023/24, including the guidance for 2024/25, which is considered inside information. For [...]
Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference
11/09/2024
SAN CARLOS, Calif., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial [...]
Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference
11/09/2024
IRVINE, Calif., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, will participate in a fireside chat [...]
Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares
11/09/2024
BOSTON and LONDON, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for [...]
UPDATE - Glass House Brands to Host Analyst & Institutional Investor Day on September 12, 2024 at the SoCal Farm in Camarillo, California
11/09/2024
LONG BEACH, Calif. and TORONTO, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Glass House Brands Inc. (“Glass House” or the “Company”) (CBOE CA: GLAS.A.U) (CBOE CA: GLAS.WT.U) (OTCQX: GLASF) (OTCQX: GHBWF), one of the fastest- [...]
IGI annonce la publication d’un article dans Nature Cancer sur l’ISB 2001, l’anticorps tri-spécifique novateur d’IGI pour le traitement du myélome multiple en rechute ou réfractaire
11/09/2024
L’article met en évidence les résultats précliniques démontrant que l’ISB 2001 peut potentiellement déjouer les mécanismes d’échappement des cellules myélomateuses pour contourner l’activité thérapeutique antitumorale [...]
Dean Schauer Appointed Chairman of the Board of Confluent Medical Technologies
11/09/2024
SCOTTSDALE, Ariz., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Confluent Medical Technologies (Confluent) announced today that Dean Schauer, who has served as the company’s Chief Executive Officer for more than a decade, has [...]
BriaCell Therapeutics Announces $8.5 Million Offering
11/09/2024
Priced At-the-Market Under Nasdaq Rules PHILADELPHIA and VANCOUVER, British Columbia, Sept. 11, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a [...]
ORYZON Receives “Intention to Grant” Communication for Patent Relating to the Use of Vafidemstat in Borderline Personality Disorder
11/09/2024
From the European Patent Office MADRID and CAMBRIDGE, Mass., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to [...]
BioNexus Gene Lab Corp Announces New Business Developments for Subsidiary Chemrex with Investment in High-Quality Color Paste Production
11/09/2024
KUALA LUMPUR, Malaysia, Sept. 11, 2024 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp (Nasdaq: BGLC, the “Company”), an emerging Biotech & Chemicals company, is pleased to announce that its subsidiary, Chemrex [...]
Ultimovacs Announces Patient Recruitment Discontinuation in LUNGVAC Trial Investigating UV1 Combined with Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer
11/09/2024
Oslo, September 11, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announced that the company has agreed with the investigators [...]

Pages